Fortune Financial Advisors’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-4,325
Closed -$651K 97
2025
Q1
$651K Sell
4,325
-7
-0.2% -$1.17K 0.56% 53
2024
Q4
$800K Hold
4,332
0.73% 42
2024
Q3
$853K Hold
4,332
0.77% 42
2024
Q2
$895K Hold
4,332
0.55% 60
2024
Q1
$1.17M Hold
4,332
0.74% 40
2023
Q4
$1.02M Buy
4,332
+186
+4% +$36.6K 0.72% 46
2023
Q3
$813K Hold
4,146
0.62% 52
2023
Q2
$872K Buy
+4,146
New +$825K 0.65% 49

Other funds holding CRL

Fortune Financial Advisors's CRL Position: Q2 2025 in Review

Fortune Financial Advisors sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 4,325 shares — an estimated $651K sold.

Fortune Financial Advisors first reported a position in CRL in Q2 2023 and held it in 8 quarters. The position peaked at $1.17M in Q1 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Fortune Financial Advisors reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Fortune Financial Advisors sold 4,325 Charles River Laboratories shares in Q2 2025, an estimated $651K.
  • Fortune Financial Advisors first reported a position in Charles River Laboratories in Q2 2023 and held it in 8 quarters.
  • Fortune Financial Advisors's Charles River Laboratories position peaked at $1.17M in Q1 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Fortune Financial Advisors's 13F filing for Q2 2025, filed 16 Jul 2025.